UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

Blood, 2010-07, Vol.116 (4), p.537-543

2010

Volltextzugriff (PDF)

High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism

American journal of physiology. Renal physiology, 2003-03, Vol.284 (3), p.F455-F466

2003

Volltextzugriff (PDF)

Signature program: a platform of basket trials

Oncotarget, 2018-04, Vol.9 (30), p.21383-21395

2018

Volltextzugriff (PDF)

IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose

American journal of physiology. Renal physiology, 2003-11, Vol.285 (5), p.F1013-F1024

2003

Volltextzugriff (PDF)

Angiotensin II Promotes Glucose-Induced Activation of Cardiac Protein Kinase C Isozymes and Phosphorylation of Troponin I

Diabetes (New York, N.Y.), 2001-08, Vol.50 (8), p.1918-1926

2001

Volltextzugriff (PDF)

Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial

Haematologica (Roma), 2011-07, Vol.96 (7), p.1055-1058

2011

Volltextzugriff (PDF)

Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D–CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study

JCO precision oncology, 2019-12 (3), p.1-10

2019

Volltextzugriff (PDF)

Follow‐up report on the 2‐year cardiac data from a deferasirox monotherapy trial

American journal of hematology, 2010-10, Vol.85 (10), p.818-819

2010

Volltextzugriff (PDF)

PKC-ε-dependent survival signals in diabetic hearts

American journal of physiology. Heart and circulatory physiology, 2005-10, Vol.289 (4), p.H1343-H1350

2005

Volltextzugriff (PDF)

Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e17043-e17043

2024

Volltextzugriff (PDF)

Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) use by US urologists and oncologists

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e17048-e17048

2024

Volltextzugriff (PDF)

Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617): A real-world United States (US) study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.81-81

2024

Volltextzugriff (PDF)

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients

Melanoma research, 2023-02, Vol.33 (1), p.38-49

2023

Volltextzugriff (PDF)

Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22102-e22102

2020

Volltextzugriff (PDF)

PKC-ε-dependent survival signals in diabetic hearts

American journal of physiology. Heart and circulatory physiology, 2005-10, Vol.58 (4), p.H1343-H1350

2005

Volltextzugriff (PDF)

PKC-{varepsilon}-dependent survival signals in diabetic hearts

American journal of physiology. Heart and circulatory physiology, 2005-10, Vol.289 (4), p.H1343-H1350

2005

Volltextzugriff (PDF)

PKC? inhibits the hyperglycemia-induced apoptosis signal in adult rat ventricular myocytes

Molecular and cellular biochemistry, 2005-01, Vol.268 (1-2), p.169-173

2005

Volltextzugriff (PDF)

IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose

American journal of physiology. Renal physiology, 2003-11, Vol.54 (5), p.F1013-F1024

2003

Volltextzugriff (PDF)

High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism

American journal of physiology. Renal physiology, 2003-03, Vol.53 (3), p.F455-F466

2003

Volltextzugriff (PDF)

Abstract B22: Outcomes and genomic mutational profiling results in patients with cancers of the head and neck treated with dovitinib in the Signature Program

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B22-B22

2015

Volltextzugriff (PDF)

Abstract A53: Outcomes and genomic mutation profiling results in a subset of patients with gynecologic cancers treated with buparlisib in the Signature Program

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A53-A53

2015

Volltextzugriff (PDF)

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2528-2528

2016

Volltextzugriff (PDF)

Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.644-644

2015

Volltextzugriff (PDF)

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Blood, 2014-12, Vol.124 (21), p.4818-4818

2014

Volltextzugriff (PDF)

The signature program, a series of tissue-agnostic, mutation-specific signal finding trials

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS2646-TPS2646

2014

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism

Signature program: a platform of basket trials

IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose

Angiotensin II Promotes Glucose-Induced Activation of Cardiac Protein Kinase C Isozymes and Phosphorylation of Troponin I

Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial

Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D–CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study

Follow‐up report on the 2‐year cardiac data from a deferasirox monotherapy trial

PKC-ε-dependent survival signals in diabetic hearts

Real-world clinical outcomes and economic burden of early discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer

Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617) use by US urologists and oncologists

Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan ( 177 Lu-PSMA-617): A real-world United States (US) study

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients

Management of pyrexia in metastatic melanoma patients: A real-world clinical experience survey study

PKC-ε-dependent survival signals in diabetic hearts

PKC-{varepsilon}-dependent survival signals in diabetic hearts

PKC? inhibits the hyperglycemia-induced apoptosis signal in adult rat ventricular myocytes

IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose

High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism

Abstract B22: Outcomes and genomic mutational profiling results in patients with cancers of the head and neck treated with dovitinib in the Signature Program

Abstract A53: Outcomes and genomic mutation profiling results in a subset of patients with gynecologic cancers treated with buparlisib in the Signature Program

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program

Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

The signature program, a series of tissue-agnostic, mutation-specific signal finding trials

Suchergebnisse filtern